questionsmedicales.fr
Métabolisme
Désalkylation
Désalkylation : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Désalkylation
Tests biochimiques
Anomalies hépatiques
Désalkylation
Imagerie médicale
Désalkylation
Enzymes hépatiques
Désalkylation
Symptômes
5
Nausées
Douleurs abdominales
Effets neurologiques
Désalkylation
Éruptions cutanées
Désalkylation
Hépatotoxicité
Désalkylation
Prévention
5
Prévention
Substances chimiques
Contrôles médicaux
Désalkylation
Éducation des patients
Médicaments
Mode de vie
Complications
Professionnels de santé
Interactions médicamenteuses
Traitements
5
Antidotes
Soins de soutien
Antiémétiques
Analgésiques
Prévention
Substances toxiques
Complications
5
Lésions hépatiques
Troubles neurologiques
Maladies chroniques
Cirrhose
Réversibilité
Traitement précoce
Surveillance clinique
Tests de laboratoire
Facteurs de risque
5
Facteurs de risque
Antécédents hépatiques
Habitudes alimentaires
Toxines
Tabagisme
Substances nocives
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Désalkylation : Questions médicales les plus fréquentes",
"headline": "Désalkylation : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Désalkylation : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-28",
"dateModified": "2025-02-22",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Désalkylation"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Métabolisme",
"url": "https://questionsmedicales.fr/mesh/D008660",
"about": {
"@type": "MedicalCondition",
"name": "Métabolisme",
"code": {
"@type": "MedicalCode",
"code": "D008660",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G03"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Déméthylation",
"alternateName": "Demethylation",
"url": "https://questionsmedicales.fr/mesh/D000073398",
"about": {
"@type": "MedicalCondition",
"name": "Déméthylation",
"code": {
"@type": "MedicalCode",
"code": "D000073398",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G03.219.500"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Déméthylation de l'ADN",
"alternateName": "DNA Demethylation",
"url": "https://questionsmedicales.fr/mesh/D000073399",
"about": {
"@type": "MedicalCondition",
"name": "Déméthylation de l'ADN",
"code": {
"@type": "MedicalCode",
"code": "D000073399",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G03.219.500.500"
}
}
}
]
}
],
"about": {
"@type": "MedicalCondition",
"name": "Désalkylation",
"alternateName": "Dealkylation",
"code": {
"@type": "MedicalCode",
"code": "D003640",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Michael R Baldwin",
"url": "https://questionsmedicales.fr/author/Michael%20R%20Baldwin",
"affiliation": {
"@type": "Organization",
"name": "Department of Biological Chemistry, University of Michigan Medical School, Ann Arbor, Michigan 48109-0600."
}
},
{
"@type": "Person",
"name": "Suzanne J Admiraal",
"url": "https://questionsmedicales.fr/author/Suzanne%20J%20Admiraal",
"affiliation": {
"@type": "Organization",
"name": "Department of Biological Chemistry, University of Michigan Medical School, Ann Arbor, Michigan 48109-0600."
}
},
{
"@type": "Person",
"name": "Patrick J O'Brien",
"url": "https://questionsmedicales.fr/author/Patrick%20J%20O%27Brien",
"affiliation": {
"@type": "Organization",
"name": "Department of Biological Chemistry, University of Michigan Medical School, Ann Arbor, Michigan 48109-0600. Electronic address: pjobrien@umich.edu."
}
},
{
"@type": "Person",
"name": "Yusuke Suzuki",
"url": "https://questionsmedicales.fr/author/Yusuke%20Suzuki",
"affiliation": {
"@type": "Organization",
"name": "Department of Hospital Pharmacy, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, Shizuoka, 431-3192, Japan."
}
},
{
"@type": "Person",
"name": "Takafumi Naito",
"url": "https://questionsmedicales.fr/author/Takafumi%20Naito",
"affiliation": {
"@type": "Organization",
"name": "Department of Hospital Pharmacy, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, Shizuoka, 431-3192, Japan. naitou@shinshu-u.ac.jp."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "The interactions of docetaxel with tumor microenvironment.",
"datePublished": "2023-04-29",
"url": "https://questionsmedicales.fr/article/37126985",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.intimp.2023.110214"
}
},
{
"@type": "ScholarlyArticle",
"name": "Dose reduction of docetaxel avoids the usage of pegfilgrastim in docetaxel plus ramucirumab therapy for recurrent nonsmall cell lung cancer.",
"datePublished": "2023-02-02",
"url": "https://questionsmedicales.fr/article/36727271",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/cnr2.1793"
}
},
{
"@type": "ScholarlyArticle",
"name": "Posterior reversible encephalopathy syndrome triggered by FLOT (5-fluorouracil, oxaliplatin, docetaxel, and calcium levofolinate) chemotherapy and thrombocytopenia (docetaxel and cisplatin) chemotherapy.",
"datePublished": "2023-05-22",
"url": "https://questionsmedicales.fr/article/37218162",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1177/10781552231177597"
}
},
{
"@type": "ScholarlyArticle",
"name": "Does castration status affect docetaxel-related adverse events? :Identification of risk factors for docetaxel-related adverse events in metastatic prostate cancer.",
"datePublished": "2022-06-29",
"url": "https://questionsmedicales.fr/article/35767376",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/pros.24406"
}
},
{
"@type": "ScholarlyArticle",
"name": "Wounding the stroma: Docetaxel's role in dormant breast cancer escape.",
"datePublished": "2023-09-13",
"url": "https://questionsmedicales.fr/article/37703292",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pbio.3002297"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Métabolisme",
"item": "https://questionsmedicales.fr/mesh/D008660"
},
{
"@type": "ListItem",
"position": 3,
"name": "Désalkylation",
"item": "https://questionsmedicales.fr/mesh/D003640"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Désalkylation - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Désalkylation",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-10",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Désalkylation",
"description": "Comment diagnostiquer une désalkylation ?\nQuels tests sont utilisés pour la désalkylation ?\nQuels signes indiquent une désalkylation ?\nLa désalkylation est-elle détectable par imagerie ?\nQuels marqueurs sont associés à la désalkylation ?",
"url": "https://questionsmedicales.fr/mesh/D003640?mesh_terms=Docetaxel#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Désalkylation",
"description": "Quels symptômes sont liés à la désalkylation ?\nLa désalkylation provoque-t-elle des effets neurologiques ?\nY a-t-il des symptômes cutanés associés ?\nLa désalkylation affecte-t-elle le foie ?\nQuels signes de toxicité sont observés ?",
"url": "https://questionsmedicales.fr/mesh/D003640?mesh_terms=Docetaxel#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Désalkylation",
"description": "Comment prévenir la désalkylation ?\nLes contrôles médicaux aident-ils à prévenir la désalkylation ?\nL'éducation des patients est-elle importante ?\nLes changements de mode de vie aident-ils ?\nLes professionnels de santé jouent-ils un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D003640?mesh_terms=Docetaxel#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Désalkylation",
"description": "Quel traitement pour une désalkylation toxique ?\nLes médicaments peuvent-ils aider à la désalkylation ?\nComment gérer les symptômes de désalkylation ?\nY a-t-il des traitements préventifs ?\nLa désalkylation nécessite-t-elle une hospitalisation ?",
"url": "https://questionsmedicales.fr/mesh/D003640?mesh_terms=Docetaxel#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Désalkylation",
"description": "Quelles complications peuvent survenir ?\nLa désalkylation peut-elle entraîner des maladies chroniques ?\nY a-t-il des risques de surdosage ?\nLes complications sont-elles réversibles ?\nComment surveiller les complications ?",
"url": "https://questionsmedicales.fr/mesh/D003640?mesh_terms=Docetaxel#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Désalkylation",
"description": "Quels sont les facteurs de risque de désalkylation ?\nL'âge influence-t-il le risque de désalkylation ?\nLes habitudes alimentaires affectent-elles le risque ?\nLe tabagisme est-il un facteur de risque ?\nLes maladies préexistantes influencent-elles le risque ?",
"url": "https://questionsmedicales.fr/mesh/D003640?mesh_terms=Docetaxel#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une désalkylation ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests biochimiques et des analyses de sang pour évaluer les métabolites."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour la désalkylation ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de toxicologie et des analyses enzymatiques sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une désalkylation ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes cliniques comme des anomalies hépatiques peuvent indiquer une désalkylation."
}
},
{
"@type": "Question",
"name": "La désalkylation est-elle détectable par imagerie ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, la désalkylation est généralement évaluée par des tests biochimiques, pas par imagerie."
}
},
{
"@type": "Question",
"name": "Quels marqueurs sont associés à la désalkylation ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les marqueurs comme les enzymes hépatiques peuvent être augmentés lors de la désalkylation."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à la désalkylation ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent inclure des nausées, des vomissements et des douleurs abdominales."
}
},
{
"@type": "Question",
"name": "La désalkylation provoque-t-elle des effets neurologiques ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des effets neurologiques comme des vertiges peuvent survenir en cas de désalkylation."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes cutanés associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées peuvent apparaître en raison de réactions aux métabolites de désalkylation."
}
},
{
"@type": "Question",
"name": "La désalkylation affecte-t-elle le foie ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut entraîner des anomalies hépatiques et une hépatotoxicité."
}
},
{
"@type": "Question",
"name": "Quels signes de toxicité sont observés ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes de toxicité incluent fatigue, confusion et jaunisse dans les cas graves."
}
},
{
"@type": "Question",
"name": "Comment prévenir la désalkylation ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter l'exposition à des substances chimiques et suivre les prescriptions médicales aide."
}
},
{
"@type": "Question",
"name": "Les contrôles médicaux aident-ils à prévenir la désalkylation ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des contrôles réguliers peuvent détecter des problèmes avant qu'ils ne deviennent graves."
}
},
{
"@type": "Question",
"name": "L'éducation des patients est-elle importante ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, informer les patients sur les risques des médicaments et des toxines est crucial."
}
},
{
"@type": "Question",
"name": "Les changements de mode de vie aident-ils ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Adopter un mode de vie sain peut réduire le risque de désalkylation et de complications."
}
},
{
"@type": "Question",
"name": "Les professionnels de santé jouent-ils un rôle ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les professionnels de santé doivent surveiller les interactions médicamenteuses et les risques."
}
},
{
"@type": "Question",
"name": "Quel traitement pour une désalkylation toxique ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement peut inclure des soins de soutien et des antidotes spécifiques selon le toxique."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils aider à la désalkylation ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments peuvent faciliter le métabolisme et l'élimination des toxines."
}
},
{
"@type": "Question",
"name": "Comment gérer les symptômes de désalkylation ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion des symptômes inclut des antiémétiques et des analgésiques pour le confort."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements préventifs ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les substances toxiques et surveiller les médicaments peut prévenir la désalkylation."
}
},
{
"@type": "Question",
"name": "La désalkylation nécessite-t-elle une hospitalisation ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Cela dépend de la gravité des symptômes et de l'exposition aux toxines, parfois nécessaire."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des lésions hépatiques, des troubles neurologiques et des réactions allergiques."
}
},
{
"@type": "Question",
"name": "La désalkylation peut-elle entraîner des maladies chroniques ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une désalkylation sévère peut contribuer à des maladies chroniques comme la cirrhose."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de surdosage ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un surdosage de substances pouvant subir désalkylation peut être fatal."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement précoce, d'autres non."
}
},
{
"@type": "Question",
"name": "Comment surveiller les complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "La surveillance clinique et les tests de laboratoire réguliers sont essentiels pour détecter les complications."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque de désalkylation ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'exposition à des toxines, l'usage de certains médicaments et des antécédents hépatiques."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque de désalkylation ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes âgées peuvent avoir un risque accru en raison d'une fonction hépatique diminuée."
}
},
{
"@type": "Question",
"name": "Les habitudes alimentaires affectent-elles le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation riche en toxines ou en médicaments peut augmenter le risque de désalkylation."
}
},
{
"@type": "Question",
"name": "Le tabagisme est-il un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme peut augmenter le risque de désalkylation en raison de l'exposition à des substances nocives."
}
},
{
"@type": "Question",
"name": "Les maladies préexistantes influencent-elles le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des maladies comme l'hépatite ou la cirrhose augmentent le risque de désalkylation."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 22/02/2025
Contenu vérifié selon les dernières recommandations médicales
2 publications dans cette catégorie
Affiliations :
Department of Biological Chemistry, University of Michigan Medical School, Ann Arbor, Michigan 48109-0600.
Publications dans "Désalkylation" :
2 publications dans cette catégorie
Affiliations :
Department of Biological Chemistry, University of Michigan Medical School, Ann Arbor, Michigan 48109-0600.
Publications dans "Désalkylation" :
2 publications dans cette catégorie
Affiliations :
Department of Biological Chemistry, University of Michigan Medical School, Ann Arbor, Michigan 48109-0600. Electronic address: pjobrien@umich.edu.
Publications dans "Désalkylation" :
2 publications dans cette catégorie
Affiliations :
Department of Hospital Pharmacy, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, Shizuoka, 431-3192, Japan.
Publications dans "Désalkylation" :
2 publications dans cette catégorie
Affiliations :
Department of Hospital Pharmacy, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, Shizuoka, 431-3192, Japan. naitou@shinshu-u.ac.jp.
Department of Pharmacy, Shinshu University Hospital, 3-1-1 Asahi, Matsumoto, Nagano, 390-8621, Japan. naitou@shinshu-u.ac.jp.
Publications dans "Désalkylation" :
2 publications dans cette catégorie
Affiliations :
Department of Hospital Pharmacy, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, Shizuoka, 431-3192, Japan.
Publications dans "Désalkylation" :
2 publications dans cette catégorie
Affiliations :
Department of Hospital Pharmacy, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, Shizuoka, 431-3192, Japan.
Publications dans "Désalkylation" :
1 publication dans cette catégorie
Affiliations :
Department of Chemistry, Texas A&M University, College Station, Texas 77843, United States.
Publications dans "Désalkylation" :
1 publication dans cette catégorie
Affiliations :
Department of Chemistry, Texas A&M University, College Station, Texas 77843, United States.
Publications dans "Désalkylation" :
1 publication dans cette catégorie
Affiliations :
Department of Chemistry, Texas A&M University, College Station, Texas 77843, United States.
Publications dans "Désalkylation" :
1 publication dans cette catégorie
Affiliations :
Kodikos Laboratories, Institut Cochin, Paris 75014, France.
Publications dans "Désalkylation" :
1 publication dans cette catégorie
Affiliations :
Kodikos Laboratories, Institut Cochin, Paris 75014, France.
Publications dans "Désalkylation" :
1 publication dans cette catégorie
Affiliations :
Department of Chemistry, Texas A&M University, College Station, Texas 77843, United States.
Publications dans "Désalkylation" :
1 publication dans cette catégorie
Affiliations :
Department of Analytical Biochemistry, Groningen Research Institute of Pharmacy, University of Groningen, A Deusinglaan 1, 9713 AV, Groningen, The Netherlands.
Publications dans "Désalkylation" :
1 publication dans cette catégorie
Affiliations :
Department of Chemical Engineering, Engineering and Technology Institute Groningen, University of Groningen, 9747 AG, Groningen, The Netherlands.
Publications dans "Désalkylation" :
1 publication dans cette catégorie
Affiliations :
Department of Drug Design, University of Groningen, A Deusinglaan 1, 9713 AV, Groningen, The Netherlands.
Publications dans "Désalkylation" :
1 publication dans cette catégorie
Affiliations :
Department of Analytical Biochemistry, Groningen Research Institute of Pharmacy, University of Groningen, A Deusinglaan 1, 9713 AV, Groningen, The Netherlands.
Publications dans "Désalkylation" :
1 publication dans cette catégorie
Affiliations :
Department of Analytical Biochemistry, Groningen Research Institute of Pharmacy, University of Groningen, A Deusinglaan 1, 9713 AV, Groningen, The Netherlands.
Publications dans "Désalkylation" :
1 publication dans cette catégorie
Affiliations :
Department of Chemical Engineering, Engineering and Technology Institute Groningen, University of Groningen, 9747 AG, Groningen, The Netherlands.
Publications dans "Désalkylation" :
1 publication dans cette catégorie
Affiliations :
Department of Drug Design, University of Groningen, A Deusinglaan 1, 9713 AV, Groningen, The Netherlands.
Publications dans "Désalkylation" :
There are several interactions within the tumor microenvironment (TME) that affect the response of cancer cells to therapy. There are also a large number of cells and secretions in TME that increase r...
Pegfilgrastim is recommended in docetaxel plus ramucirumab (DTX + RAM) therapy for recurrent nonsmall cell lung cancer (NSCLC) because of the associated frequency of febrile neutropenia (FN). However,...
Twenty-two patients with recurrent NSCLC who received DTX + RAM therapy at the Hiroshima Prefectural Hospital. The cut-off value which is the most unlikely to cause FN without the combined use of pegf...
Pegfilgrastim can be discontinued when the dose of DTX is reduced to <48 mg/m...
Posterior reversible encephalopathy syndrome is a clinical and imaging syndrome characterized by endothelial dysfunction, blood-brain barrier disruption, and vasogenic edema. The common clinical sympt...
We describe the case of a middle-aged woman with gastric cancer. She was under treatment by fluorouracil, leucovorin, oxaliplatin, and docetaxel regimen and thrombocytopenia regimen after tumor progre...
After admission, she was treated to control blood pressure, reduce brain edema, expand blood vessels, improve consciousness, and symptomatic support treatment. 3 days after the onset of the disease, h...
This is the first report that posterior reversible encephalopathy syndrome is caused by a thrombocytopenia regimen, and our case highlights the pathogenic role of a thrombocytopenia regimen in posteri...
Docetaxel-related adverse events (AEs) such as neutropenia and febrile neutropenia (FN) can be life-threatening. A previous in vivo study raised the hypothesis that the castration status affects the r...
We retrospectively analyzed the records of 265 mPCa patients treated with docetaxel, comprising 92 patients with metastatic hormone-sensitive prostate cancer (mHSPC) and 173 patients with metastatic c...
The rate of patients who received primary prophylaxis against neutropenia was higher in those with the mHSPC compared with those with the mCRPC (7.5% vs. 33%, p < 0.001). Among the patients without pr...
Castration status did not affect the risk of severe neutropenia or FN in mPCa patients treated with docetaxel regardless of the disease state. Failure to provide primary prophylaxis and advanced patie...
The mechanistic underpinnings of breast cancer recurrence following periods of dormancy are largely undetermined. A new study in PLOS Biology reveals that docetaxel-induced injury of tumour stromal ce...
We aimed to study the relation between pharmacokinetics (PK) and pharmacodynamics (PD) of docetaxel in early breast cancer and recommend a target exposure....
A PK/PD study was performed in 27 early breast cancer patients treated with doxorubicin and cyclophosphamide for 4 cycles followed by 4 cycles of docetaxel 75-100 mg/m...
Docetaxel clearance showed no change over the 4 treatment cycles, but a gradual increase in the volume of distribution was observed. One third of the patients had at least 1 dose reduction of docetaxe...
We report for the first time a relation between docetaxel exposure and toxicity and recommend specific targets of drug exposure with implications for the clinical management of early breast cancer pat...
Docetaxel is a cytotoxic taxane frequently used to treat patients with various cancers, including non-small cell lung cancer (NSCLC). Docetaxel is known to cause acute myalgias, arthralgias, and neuro...
A majority of prostate cancer cells are in a non-proliferating, G...
Publically available, anonymous, clinical data was obtained from cBioPortal for analysis. RNAi and prostate cancer cell lines were utilized to investigate SNHG1 in vitro. We measured G...
We discovered that in prostate cancer patients from The Cancer Genome Atlas (TCGA) data set, high SNHG1 expression in localized tumors correlated with reduced progression-free survival, and in a data ...
Overall, these results indicate SNHG1 has complex roles in prostate cancer, as it stimulates cell cycle entry and disease progression, but sensitizes cells to docetaxel treatment....
Docetaxel is commonly used for treatment of castration-resistant prostate cancer. Unfortunately, many prostate cancer patients develop resistance to docetaxel. Clinical markers less invasive than biop...
Drug-induced neutropenia is the main reason for the dose limitation of docetaxel in patients with breast cancer. The area under the drug concentration-time curve (AUC) of docetaxel is associated with ...
Docetaxel plasma concentration, demographics, clinical data, and related laboratory data were collected. PopPK analyses were performed using a nonlinear mixed-effect modelling program. The docetaxel A...
Among the 70 participants, 47 (67.1%) developed severe neutropenia. The PopPK analysis showed that the typical drug clearance (CL) rate was 37.4 L/h. Age was a significant covariate of CL rate, and as...
We developed a docetaxel PopPK model for patients with early-stage breast cancer. Age and AST and ALB levels were significant covariates. AUC estimated using the MAPB method can predict the toxicity o...
Chinese Clinical Trial Center Registry (ChiCTR2200056460)....